Biopharma CDMOs need to rethink production according to Resilience CEO Rahul Singhvi, who says industry must learn to make a new generation of complex products. Advances in biological science in recent years are helping the biopharmaceutical industry to start unlocking the potential of cell and gene therapies. For example, in the past few months the US FDA has approved two cell based cancer meds – Abecma (idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel) – further underlining the cell therapy sector’s potential.…
